PeptideDB

Neuropeptide Y (13-36), amide, human

CAS: 122341-40-6 F: C134H207N41O36S W: 3000.40

Neuropeptide Y (13-36), amide, human is a selective neuropeptide Y2 receptor agonist.
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Neuropeptide Y (13-36), amide, human is a selective neuropeptide Y2 receptor agonist[1].
In Vivo Neuropeptide Y (13-36) (intraventricular injection; 25-3000 pmol) produces a dose-dependent increase (up to 14%; ED50 value of 0.3 nmol for overall effects and 0.97 nmol for the peak effects) in mean arterial blood pressure in the awake, unrestrained male rat without affecting heart rate. Central administration of porcine Neuropeptide Y (13-36) produces marked vasodepressor and bradycardic actions in the anaesthetized α-chloralose and in the awake unrestrained male rat[1].Neuropeptide Y (13-36) (intracerebroventricular injection; 50 ng; alone; injected 30 and 15 min before measurements) injected into naïve mice impairs social novelty preference, but not sociability, and this effect is inhibited by the NPY Y2 receptor antagonist BIIE 0246[2]. Animal Model:
Name Neuropeptide Y (13-36), amide, human
CAS 122341-40-6
Sequence Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2
Shortening PAEDMARYYSALRHYINLITRQRY-NH2
Formula C134H207N41O36S
Molar Mass 3000.40
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Reference [1]. Aguirre JA, et al. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat. Neurosci Lett. 1990 Oct 2;118(1):5-8. [2]. Daiki Ueda, et al. Increase in neuropeptide Y activity impairs social behaviour in association with glutamatergic dysregulation in diabetic mice. Br J Pharmacol. 2021 Feb;178(3):726-740.